Stability of salivary concentrations of the newer antiepileptic drugs in the postal system

Therapeutic Drug Monitoring

Volumn 27, Issue 5, 2005, Pages 576-579

  Jones, Mikael D ^a,c   Ryan, Melody ^a   Miles, Michael V ^b   Tang, Peter H ^b   Fakhoury, Toufic A ^a   DeGrauw, Ton J ^b   Baumann, Robert J ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Antiepileptic drugs; Mail; Postal service; Saliva; Stability

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; LAMOTRIGINE; OXCARBAZEPINE; TOPIRAMATE; ZONISAMIDE;

ADOLESCENT; ADULT; ANTICONVULSANT THERAPY; ARTICLE; CHILD; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONVULSION; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; DRUG SALIVA LEVEL; DRUG STABILITY; FEMALE; FREEZING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LABORATORY DIAGNOSIS; MALE; NON INVASIVE MEASUREMENT; PATIENT CARE; POSTAL MAIL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; WILCOXON SIGNED RANKS TEST;

ADOLESCENT; ADULT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; DRUG STABILITY; FEMALE; HUMANS; MALE; MIDDLE AGED; POSTAL SERVICE; SALIVA; SEASONS; SPECIMEN HANDLING;

EID: 26444528564     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000171869.56817.ae     Document Type: Article

References (21)

1. Knott C, Felicity R. The place of saliva in antiepileptic drug monitoring. Ther Drug Monit. 1984;6:35-41.
2. Miles MV, Tennison MB, Greenwood RS, et al. Evaluation of the Ames Seralyzer for the determination of carbamazepine, phenobarbital, and phenytoin concentrations in saliva. Ther Drug Monit. 1990;12:501-510.
3. Miles MV, Tennison MB, Greenwood RS. Intraindividual variability of carbamazepine, phenobarbital, and phenytoin concentrations in saliva. Ther Drug Monit. 1991;13:166-171.
4. Liu H, Delgado M. Therapeutic drug concentration monitoring using saliva samples. Clin Pharmacokinet. 1999;36:453-470.
5. Ryan M, Grim SA, Miles MV, et al. Correlation of lamotrigine concentrations between serum and saliva. Pharmacotherapy. 2003;23:1550-1557.
6. Trnavska Z, Krejcova H, Tkaczykovam Z, et al. Pharmacokinetics of lamotrigine (Lamictal) in plasma and saliva. Eur J Drug Metab Pharmacokinet. 1992;3:211-215.
7. Tsiropoilos I, Kristensen O, Klitgaard NA. Saliva and serum concentration of lamotrigine in patients with epilepsy. Ther Drug Monit. 2000;22:517-521.
8. Grim SA, Ryan MA, Miles MV, et al. Correlation of levetiracetam concentrations between serum and saliva. Ther Drug Monit. 2003;25:61-66.
9. Kristensen O, Klitgaard NA, Jönsson B, et al. Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations. Acta Neurol Scand. 1983;68:145-150.
10. Kristensen O, Klitgaard NA. Use of saliva for monitoring oxcarbazepine therapy in epileptic patients. Eur J Clin Pharmacol. 1986;31:91-94.
11. Cardot JM, Degen P, Flesch G, et al. Comparison of plasma and saliva concentrations of the active monohydroxy metabolite of oxcarbazepine in patients at steady state. Biopharm Drug Distrib. 1995;16:603-614.
12. Miles MV, Tang PH, Ryan MA, et al. Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbamazepine (MHD). Ther Drug Monit. 2004;26:300-304.
13. Miles MV, Tang PH, Glauser TA, et al. Topiramate concentrations in saliva: an alternative to serum monitoring. Pediatr Neurol. 2003;29:143-147.
14. Kumagai N, Seki T, Yamada T, et al. Concentrations of zonisamide in serum, free fraction, mixed saliva, and cerebrospinal fluid in epileptic children treated with monotherapy. Jpn J Psychiatry Neurol. 1993;47:291-292.
15. Tennison M, Ali I, Miles MV, et al. Feasibility and acceptance of salivary monitoring of antiepileptic drugs via the US Postal Service. Ther Drug Monit. 2004;26:295-299.
16. Rosenthal E, Hoffer E, Ben-Aryeh H, et al. Use of saliva in home monitoring carbamazepine levels. Epilepsia. 1995;36:72-74.
17. Baumann RJ, Ryan M, Yelowitz A. Physician preference for antiepileptic drug concentration testing. Pediatr Neurol. 2004;30:29-32.
18. Glauser TA, Pippenger CE. Controversies in blood-level monitoring: reexamining its role in the treatment of epilepsy. Epilepsia. 2000;41(suppl.8):S6-S15.
19. Gorodischer R, Burtin P, Hwang P, et al. Saliva versus blood sampling for therapeutic drug monitoring in children: patient and parental preferences and an economic analysis. Ther Drug Monit. 1994;16:437-443.
20. Bienvenu OJ, Eaton WW. The epidemiology of blood-injection-injury phobia. Psychol Med. 1998;28:1129-1136.
21. Bauchner H, Vinci R, Bak S, et al. Parents and Procedures: a randomized controlled trial. Pediatrics. 1996;98:861-867.